Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma

• DOI: 10.1007/s11060-008-9676-4
• Publication Date: 2008-08-18T16:11:10Z
• Authors: Francesca Valcamo...; Vittorio Ferrari; Vito Amoroso; Giovanni Rangoni; Edda Simoncini; Patrizia Marpicati; Lucia Vassalli; Salvatore Grisanti; Giovanni Marini
• Keywords: Cerebral Cortex; Niacinamide; Brain Neoplasms; Pyridines; Phenylurea Compounds; Benzenesulfonates; Antineoplastic Agents; Sorafenib; Advanced renal cell carcinoma; Sorafenib; Brain metastases; Magnetic Resonance Imaging; Kidney Neoplasms; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Humans; Female; Carcinoma, Renal Cell; Aged

We report the case of a 75-year old woman who received sorafenib (Nexavar), Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma. After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis. To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.